Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations
Authors:
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in miceVaccine, 2009
- Immunogenicity of a Whole-Cell Pertussis Vaccine with Low Lipopolysaccharide Content in InfantsClinical and Vaccine Immunology, 2009
- Current status and progress of prepandemic and pandemic influenza vaccine developmentExpert Review of Vaccines, 2009
- Alum adjuvanticity: Unraveling a century old mysteryEuropean Journal of Immunology, 2008
- A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell CultureNew England Journal of Medicine, 2008
- Major Issues and Challenges of Influenza Pandemic Preparedness in Developing CountriesEmerging Infectious Diseases, 2008
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006
- From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenzaNature Reviews Microbiology, 2004